DocMorris Raises 2026 Revenue Growth Outlook to About 15% as Prescriptions Accelerate More Than 90%
Key Facts
DocMorris raised its forecast for 2026 external revenue growth to about 15% on November 12, from a previous range of 12.5% to 15%, according to a company statement issued during its Capital Markets Day. The update reflects the performance of its prescription-drug business, whose revenue growth accelerated to more than 90% year over year in October, the company said. In light of this momentum, DocMorris now expects the prescription business to grow by about 60% for the full year. The company said its other annual and medium-term targets were unchanged. It held its Capital Markets Day in Heerlen, the Netherlands, on November 12, 2026.
October's growth and the full-year forecast point to an accelerating trajectory for the prescription business, which recorded annual growth of 33.2% in 2025, when its revenue reached 234.8 million Swiss francs. In the same year, non-prescription external revenue increased 7.1%, according to company data. In the third quarter of 2026, total external revenue rose 21.5% year over year to 342.7 million Swiss francs. External revenue growth was 15.5% in the first nine months of the year. These indicators put the 2026 external revenue growth forecast of about 15% in the context of the company's performance during the year, with its other targets unchanged.
In its third-quarter results, DocMorris reported adjusted earnings before interest, taxes, depreciation and amortization of 0.6 million Swiss francs, saying it had reached its break-even target ahead of schedule. The company reaffirmed its aim of achieving free cash flow break-even in 2027. It also said revenue growth accelerated again in the third quarter and that patients were responding well to its offerings. The number of active customers rose by 1.5 million year over year to 13.1 million in the quarter. The company had served more than 12 million active customers and generated external revenue of 1,186 million Swiss francs in 2025.
Alongside the forecast update, DocMorris announced that TeleClinic is expanding into Switzerland through the acquisition of telemedicine provider Medi24 from Allianz Partners. Medi24 is based in Liebefeld and was described by the company as one of Switzerland's leading telemedicine providers. Medi24 provides contractually guaranteed initial access to telemedicine services for more than 4.6 million insured people, or about 50% of all insured people in the country, according to company data dated November 4, 2026. DocMorris said the acquisition would make a significant contribution to TeleClinic's earnings before interest, taxes, depreciation and amortization in the first full year of 2027. The Swiss expansion adds a new business to the group's digital healthcare operations.
The company is scheduled to report its 2026 revenue on January 19, 2027, according to its financial calendar. It then plans to announce its 2026 annual results and 2027 outlook on March 18, 2027. The first disclosure will provide the full-year revenue figures after the company raised its growth forecast to about 15%. The March announcement will combine the annual results and outlook for the following period in one release. Until then, the other annual and medium-term targets remain at the levels the company said were unchanged.